The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer
Objective: To investigate the real-world efficacy and toxicity of paclitaxel-cisplatin-bevacizumab and identify prognostic factors for paclitaxel-cisplatin-bevacizumab in platinum-naïve primary stage IVB cervical cancer. Materials and methods: We retrospectively reviewed patients with stage IVB cerv...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Taiwanese Journal of Obstetrics & Gynecology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S102845592400278X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841553909203599360 |
|---|---|
| author | Junhwan Kim Eun-Byul Park Shin-Wha Lee Jeong-Yeol Park Dae-Yeon Kim Dae-Shik Suh Jong-Hyeok Kim Yong-Man Kim Ju-Hyun Kim |
| author_facet | Junhwan Kim Eun-Byul Park Shin-Wha Lee Jeong-Yeol Park Dae-Yeon Kim Dae-Shik Suh Jong-Hyeok Kim Yong-Man Kim Ju-Hyun Kim |
| author_sort | Junhwan Kim |
| collection | DOAJ |
| description | Objective: To investigate the real-world efficacy and toxicity of paclitaxel-cisplatin-bevacizumab and identify prognostic factors for paclitaxel-cisplatin-bevacizumab in platinum-naïve primary stage IVB cervical cancer. Materials and methods: We retrospectively reviewed patients with stage IVB cervical cancer who received paclitaxel-cisplatin-bevacizumab as first-line treatment between July 2015 and December 2021 at Asan Medical Center, Korea. Patient data including clinicopathologic characteristics, imaging, paclitaxel-cisplatin-bevacizumab administration, recurrence, and survival were collected. Results: Overall, 61 patients were included in this study. The median age of the patients was 56 (range, 28−79) years. Patients received a median of 9 (range, 2−30) cycles of paclitaxel-cisplatin-bevacizumab. The most common adverse event (all grades) during treatment was azotemia (80.3 %). Dose reduction and drug interruption were conducted in 41.0 % and 26.2 % of patients, respectively. The median progression-free survival (PFS) and the median overall survival (OS) were 11.8 (95 % confidence interval [CI], 9.3−14.2) and 24.3 (95 % CI, 16.9−31.7) months, respectively. Multivariate analysis indicated that cervical mass size reduction rate ≥40 % at the longest diameter was an independent prognostic factor for PFS (adjusted hazard ratio, 0.24; 95 % CI, 0.11−0.53; p < 0.001). The median PFS of the patients with cervical mass size reduction rate ≥40 % and <40 % were 13.7 (95 % CI, 10.9−16.5) and 5.9 (95 % CI, 0−12.6) months, respectively (p < 0.001). Conclusion: Paclitaxel-cisplatin-bevacizumab is effective and tolerable as a first-line treatment for platinum-naïve primary stage IVB cervical cancer. Cervical mass size reduction rate ≥40 % during paclitaxel-cisplatin-bevacizumab treatment might be a potential prognostic factor for PFS in patients with platinum-naïve primary stage IVB cervical cancer. |
| format | Article |
| id | doaj-art-a21c5d5a90b24b98a46bfd4d6d13323e |
| institution | Kabale University |
| issn | 1028-4559 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Taiwanese Journal of Obstetrics & Gynecology |
| spelling | doaj-art-a21c5d5a90b24b98a46bfd4d6d13323e2025-01-09T06:12:50ZengElsevierTaiwanese Journal of Obstetrics & Gynecology1028-45592025-01-016416167The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancerJunhwan Kim0Eun-Byul Park1Shin-Wha Lee2Jeong-Yeol Park3Dae-Yeon Kim4Dae-Shik Suh5Jong-Hyeok Kim6Yong-Man Kim7Ju-Hyun Kim8Center for Gynecologic Cancer, National Cancer Center, Goyang 10408, Republic of KoreaDepartment of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of KoreaDepartment of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of KoreaDepartment of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of KoreaDepartment of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of KoreaDepartment of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of KoreaDepartment of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of KoreaDepartment of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of KoreaDepartment of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea; Corresponding author. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea.Objective: To investigate the real-world efficacy and toxicity of paclitaxel-cisplatin-bevacizumab and identify prognostic factors for paclitaxel-cisplatin-bevacizumab in platinum-naïve primary stage IVB cervical cancer. Materials and methods: We retrospectively reviewed patients with stage IVB cervical cancer who received paclitaxel-cisplatin-bevacizumab as first-line treatment between July 2015 and December 2021 at Asan Medical Center, Korea. Patient data including clinicopathologic characteristics, imaging, paclitaxel-cisplatin-bevacizumab administration, recurrence, and survival were collected. Results: Overall, 61 patients were included in this study. The median age of the patients was 56 (range, 28−79) years. Patients received a median of 9 (range, 2−30) cycles of paclitaxel-cisplatin-bevacizumab. The most common adverse event (all grades) during treatment was azotemia (80.3 %). Dose reduction and drug interruption were conducted in 41.0 % and 26.2 % of patients, respectively. The median progression-free survival (PFS) and the median overall survival (OS) were 11.8 (95 % confidence interval [CI], 9.3−14.2) and 24.3 (95 % CI, 16.9−31.7) months, respectively. Multivariate analysis indicated that cervical mass size reduction rate ≥40 % at the longest diameter was an independent prognostic factor for PFS (adjusted hazard ratio, 0.24; 95 % CI, 0.11−0.53; p < 0.001). The median PFS of the patients with cervical mass size reduction rate ≥40 % and <40 % were 13.7 (95 % CI, 10.9−16.5) and 5.9 (95 % CI, 0−12.6) months, respectively (p < 0.001). Conclusion: Paclitaxel-cisplatin-bevacizumab is effective and tolerable as a first-line treatment for platinum-naïve primary stage IVB cervical cancer. Cervical mass size reduction rate ≥40 % during paclitaxel-cisplatin-bevacizumab treatment might be a potential prognostic factor for PFS in patients with platinum-naïve primary stage IVB cervical cancer.http://www.sciencedirect.com/science/article/pii/S102845592400278XBevacizumabCervical cancerCisplatinPaclitaxelPrognostic factorSurvival |
| spellingShingle | Junhwan Kim Eun-Byul Park Shin-Wha Lee Jeong-Yeol Park Dae-Yeon Kim Dae-Shik Suh Jong-Hyeok Kim Yong-Man Kim Ju-Hyun Kim The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer Taiwanese Journal of Obstetrics & Gynecology Bevacizumab Cervical cancer Cisplatin Paclitaxel Prognostic factor Survival |
| title | The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer |
| title_full | The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer |
| title_fullStr | The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer |
| title_full_unstemmed | The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer |
| title_short | The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer |
| title_sort | real world efficacy and toxicity of first line paclitaxel and cisplatin with bevacizumab in platinum naive primary stage ivb cervical cancer |
| topic | Bevacizumab Cervical cancer Cisplatin Paclitaxel Prognostic factor Survival |
| url | http://www.sciencedirect.com/science/article/pii/S102845592400278X |
| work_keys_str_mv | AT junhwankim therealworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT eunbyulpark therealworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT shinwhalee therealworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT jeongyeolpark therealworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT daeyeonkim therealworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT daeshiksuh therealworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT jonghyeokkim therealworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT yongmankim therealworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT juhyunkim therealworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT junhwankim realworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT eunbyulpark realworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT shinwhalee realworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT jeongyeolpark realworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT daeyeonkim realworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT daeshiksuh realworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT jonghyeokkim realworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT yongmankim realworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer AT juhyunkim realworldefficacyandtoxicityoffirstlinepaclitaxelandcisplatinwithbevacizumabinplatinumnaiveprimarystageivbcervicalcancer |